Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

B4

Novel approach for a non-invasive diagnosis of chronic rhinosinusitis with nasal polyps

Dr Sarina Müller-Hübner, Friedrich-Alexander Universität Erlangen-Nürnberg

Bayerische Patentallianz GmbH


Challenge

As one of the most common chronic diseases worldwide and with a prevalence of approx. 10-15% of the population in developed countries, chronic rhinosinusitis (CRS) is the cause of significant costs to health systems and economies. Typical symptoms include a blocked nose, a persistent pressure in the paranasal sinuses and a continuous discharge of thin nasal mucus fluid. As a subtype, chronic rhinosinusitis with nasal polyps (CRSwNP) presents with a persistent expansion of the epithelium lining the inner nose. These fleshy swellings are believed to arise due to chronic inflammatory processes in the nasal mucosa. Patients often present with comorbidities such as asthma and suffer from recurring infections and a loss of smell. The molecular mechanism of this aberrant proliferation remains unclear making CRSwNP difficult to treat. Although symptoms can be alleviated trough surgical removal and intranasal administration of steroids, the recurrence rate is high. Diagnostic procedures include uncomfortable endoscopic tissue examinations of the nasal mucous membrane as well as laborious and cost-intense CT scans. For this reason, there is a great need for a less subjective and more reliable diagnosis of CRSwNP to start treatment as fast as possible.


Technology

Here, we present the protease Pappalysin-A (PAPP-A) as a novel biomarker for the non-invasive diagnosis of CRSwNP. PAPP-A is significantly upregulated in polyp tissues and can be easily purified from exosomes in nasal mucus samples or whole mucus as well as blood samples. Importantly, mucus retrieval is a non-invasive procedure and detection of PAPP-A is possible with commercially available kits (ELISA). In combination with other measured biomarkers, PAPP-A provides a unique and reproducible biosignature outperforming previous diagnostic methodologies. Moreover, its expression can also mirror disease progression and predict early recurrences. Additionally, PAPP-A can indicate response rate to steroids during treatment course.


Commercial Opportunity

• Polyp-specific diagnostic marker for CRSwNP

• Patient-friendly and non-invasive detection using commercial kits, e.g. ELISA

• Correlation with polyp growth enables more reliable disease monitoring


Development Status

Proof-of-concept in large patient cohort.


Patent Situation

PCT filed in 2019


Further Reading

Mueller SK et al, Escalation in Mucus Cystatin 2, Pappalysin-A and Periostin Levels Over Time Predict Need for Recurrent Surgery in CRSwNP, International Forum of Allergy and Rhinology, 2019 Oct;9(10):1212-1219.


 

Novel approach for a non-invasive diagnosis of chronic rhinosinusitis with nasal polyps